Novo Nordisk (NVO) Declines More Than Market: Some Information for Investors

Novo Nordisk (NVO) closed the most recent trading day at $37.45, moving -2.55% from the previous trading session. This change lagged the S&P 500's 1.36% loss on the day. On the other hand, the Dow registered a loss of 1.64%, and the technology-centric Nasdaq decreased by 1.46%.

The drugmaker's stock has dropped by 22.16% in the past month, falling short of the Medical sector's loss of 5.66% and the S&P 500's loss of 1.76%.

Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings disclosure. The company is forecasted to report an EPS of $0.86, showcasing a 6.52% downward movement from the corresponding quarter of the prior year. Simultaneously, our latest consensus estimate expects the revenue to be $11.23 billion, showing a 1.99% escalation compared to the year-ago quarter.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.38 per share and a revenue of $43.91 billion, representing changes of -14.65% and -6.13%, respectively, from the prior year.

Any recent changes to analyst estimates for Novo Nordisk should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.59% upward. Novo Nordisk currently has a Zacks Rank of #3 (Hold).

From a valuation perspective, Novo Nordisk is currently exchanging hands at a Forward P/E ratio of 11.36. This expresses a discount compared to the average Forward P/E of 15.12 of its industry.

The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 174, finds itself in the bottom 29% echelons of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow NVO in the coming trading sessions, be sure to utilize Zacks.com.

Free Report: Profiting from the 2nd Wave of AI Explosion

The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.

Investors who bought shares like Nvidia at the right time have had a shot at huge gains.

But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.

Zacks' AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.

Access AI Boom 2.0 now, absolutely free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novo Nordisk A/S (NVO): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research